YOT TEERAWATTANANONa, PRITAPORN KINGKAEWa, TANUNYA KOOPITAKKAJORNa,SITAPORN YOUNGKONGa,b,*, NATTHA TRITASAVITc, PATSRI SRISUWANd and SRIPEN TANTIVESSa aHealth Intervention and Technology Assessment Program (HITAP), Nonthaburi, Thailand bDepartment of Pharmacy, Faculty of Pharmacy, Mahidol Universi

Title: Public lecture on ‘Value for a QALY in Asia: Results and potential use in policy decision making’Date: September 2, 2013.Place: Rembrandt Hotel, Bangkok ( www.rembrandtbkk.com )HITAP together with HTAsiaLink host a public lecture under the topic ‘Value for a QALY in Asia: Results and potentia

President Obama’s health care law is putting new strains on some of the nation’s most hard-pressed hospitals, by cutting aid they use to pay for emergency care for illegal immigrants, which they have long been required to provide.The federal government has been spending $20 billion annually to reimb

Abstract Disease prioritization for inclusion into Thailand’s population-based screening benefit package Sitaporn Youngkong*, Patsri Srisuwan†, Tanunya Koopitakkajorn*, Pritaporn Kingkaew*, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess*, Kanitta Bundhamcharoen#, Yot Teerawattananon* *He

Government use licenses in Thailand: an assessment of the health and economic impacts Inthira Yamabhai, Adun Mohara, Sripen Tantivess*, Kakanang Chaisiri and Yot Teerawattananon. Health Intervention and Technology Assessment Program (HITAP) Background Between 2006 and 2008, Thailand’s Mi

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Due to the increasing burden of non-communicable diseases (NCDs) in aging populations and the prevalence of unhealthy lifestyles, end-stage renal disease (ESRD) that results from NCDs is a growing concern in Indonesia. With the target of achieving Universal Health Coverage (UHC) by 2019, public prov

As countries being their COVID-19 vaccinationation campaigns, an increasing number of public and private sectors in many settings are considering the introduction of COVID-19 vaccination certificates or similar instruments as a safe passage into the new normal. By facilitating the resumption of travel and economic activities, they can play an essen